According to a recent LinkedIn post from Beacon Therapeutics, the company plans to deliver five scientific presentations at the ARVO 2026 Annual Meeting in Denver. The post highlights ongoing work across its ocular gene therapy pipeline, with a particular focus on X-linked retinitis pigmentosa and geographic atrophy.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post indicates that Beacon expects to share a 12-month safety and efficacy update from the phase 2 DAWN trial of its lead candidate, laru-zova, for X-linked retinitis pigmentosa. Additional presentations are expected to cover insights from the pivotal VISTA trial and long-term safety data from the HORIZON trial.
Beacon’s LinkedIn communication also points to updates on BTX-001, its investigational intravitreal gene therapy for geographic atrophy secondary to dry age-related macular degeneration. For investors, these data disclosures at a major ophthalmology meeting may provide incremental read‑through on clinical risk, competitive positioning in retinal gene therapy, and potential future partnering or fundraising opportunities.